ESAIY Overview
Upcoming Projects (ESAIY)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (ESAIY)
-
Q4 #3: Discussing the current treatment landscape for Alzheimer's including Eisai/Biogen's Leqembi and Eli Lilly's recently approved Kisunla (donanemab).
Tickers: BIIB, ESAIY
Executed On: Dec 16, 2024 at 01:30 PM EST -
Q4 #2: Discussing the current treatment landscape for Alzheimer's including Eisai/Biogen's Leqembi and Eli Lilly's recently approved Kisunla (donanemab).
Tickers: BIIB, ESAIY
Executed On: Nov 13, 2024 at 10:00 AM EST -
Q4 #1: Discussing the current treatment landscape for Alzheimer's including Eisai/Biogen's Leqembi and Eli Lilly's recently approved Kisunla (donanemab).
Tickers: BIIB, ESAIY
Executed On: Oct 08, 2024 at 10:00 AM EDT -
Q3 #3: Discussing the current treatment landscape for Alzheimer's including Eisai/Biogen's Leqembi and Eli Lilly's recently approved Kisunla (donanemab).
Tickers: BIIB, ESAIY
Executed On: Sep 10, 2024 at 12:00 PM EDT -
Q3 #2: Discussing the current treatment landscape for Alzheimer's including Eisai/Biogen's Leqembi and Eli Lilly's recently approved Kisunla (donanemab).
Tickers: BIIB, ESAIY
Executed On: Aug 14, 2024 at 04:00 PM EDT -
Q3 #1: Discussing the current treatment landscape for Alzheimer's including Eisai/Biogen's Leqembi and Eli Lilly's recently approved Kisunla (donanemab).
Tickers: BIIB, ESAIY
Executed On: Jul 31, 2024 at 06:00 PM EDT -
A Second Opinion: Speaking on the potential of Alzheon Inc's investigational oral agent ALZ-801/valiltramiprosate for Alzheimer's Disease
Tickers: ALZHEON INC., ESAIY, BIIB, LLY
Executed On: Jul 25, 2024 at 06:00 PM EDT -
Speaking on the potential of Alzheon Inc's investigational oral agent ALZ-801/valiltramiprosate for Alzheimer's Disease
Tickers: ALZHEON INC., ESAIY, BIIB, LLY
Executed On: Jul 16, 2024 at 01:30 PM EDT -
Q2 #5: Digging into the Alzheimer's Landscape: Comparing Eisai/Biogen's Leqembi & Lilly's donanemab and novel therapies in development.
Tickers: BIIB, ESAIY
Executed On: Jun 27, 2024 at 06:15 PM EDT -
Q2 #4: Digging into the Alzheimer's Landscape: Comparing Eisai/Biogen's Leqembi & Lilly's donanemab and novel therapies in development.
Tickers: BIIB, ESAIY
Executed On: Jun 06, 2024 at 04:00 PM EDT -
Q2 #3: Digging into the Alzheimer's Landscape: Comparing Eisai/Biogen's Leqembi & Lilly's donanemab and novel therapies in development.
Tickers: BIIB, ESAIY
Executed On: May 09, 2024 at 04:30 PM EDT -
Q2 #2: Digging into the Alzheimer's Landscape: Comparing Eisai/Biogen's Leqembi & Lilly's donanemab and novel therapies in development.
Tickers: BIIB, ESAIY
Executed On: May 01, 2024 at 03:00 PM EDT -
Q2 #1: Digging into the Alzheimer's Landscape: Comparing Eisai/Biogen's Leqembi & Lilly's donanemab and novel therapies in development.
Tickers: BIIB, ESAIY
Executed On: Apr 10, 2024 at 01:00 PM EDT -
5: Digging into the Alzheimer's Landscape: Comparing Eisai/Biogen's Leqembi & Lilly's donanemab and novel therapies in development
Tickers: BIIB, ESAIY
Executed On: Feb 23, 2024 at 10:00 AM EST -
4: Digging into the Alzheimer's Landscape: Eisai/Biogen's Leqembi and novel therapies in development.
Tickers: BIIB, ESAIY
Executed On: Feb 20, 2024 at 02:00 PM EST -
3: Digging into the Alzheimer's Landscape: Comparing Eisai/Biogen's Leqembi & Lilly's donanemab and novel therapies in development
Tickers: BIIB, ESAIY, LLY
Executed On: Feb 15, 2024 at 05:00 PM EST -
A Second View: Digging into the Alzheimer's Landscape: Comparing Eisai/Biogen's Leqembi & Lilly's donanemab and novel therapies in development
Tickers: LLY, ESAIY, BIIB
Executed On: Jan 26, 2024 at 01:00 PM EST -
Digging into the Alzheimer's Landscape: Comparing Eisai/Biogen's Leqembi & Lilly's donanemab and novel therapies in development
Tickers: ESAIY, BIIB, LLY
Executed On: Jan 05, 2024 at 03:00 PM EST
Upcoming & Overdue Catalysts (ESAIY)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (ESAIY)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
